ArticleRespiratory care2023
Delivery of Aerosolized Bronchodilators by High-Flow Nasal Cannula During COPD Exacerbation.
Article in Respiratory care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Bronchodilator Efficacy of High-Flow Nasal Cannula in COPD: Vibrating Mesh Nebulizer Versus Jet Nebulizer.Respiratory care · 2024Trial
- High-flow nasal cannula in severe asthma exacerbations: current evidence and clinical perspectives.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Short-acting βInternal medicine (Tokyo, Japan) · 2025Article
- Physiological effects and clinical evidence of high-flow nasal cannula during acute exacerbation in COPD patients: A narrative review.Journal of intensive medicine · 2025Review
- High-flow nasal cannula versus non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease with acute-moderate hypercapnic respiratory failure: a retrospective study.Frontiers in medicine · 2025Article
- High-Flow Nasal Aerosol Therapy; Regional Aerosol Deposition and Airway Responsiveness.Journal of aerosol medicine and pulmonary drug delivery · 2024Article
- Effect of high-flow nasal cannula at different flow rates on diaphragmatic function in subjects recovering from an acute exacerbation of COPD: a physiological prospective pilot study.Journal of anesthesia, analgesia and critical care · 2024Article
- In Vivo Deposition of High-Flow Nasal Aerosols Using Breath-Enhanced Nebulization.Pharmaceutics · 2024Article
- The Impact of Various High-Flow Nasal Cannula Devices on Transnasal Aerosol Delivery.Respiratory care · 2023Article
- Transnasal Aerosol Delivery via HFNC: A Question of Safety and Efficacy.Respiratory care · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBronchodilator delivery via a high-flow nasal cannula (HFNC) has generated interest in recent years. The efficacy of in-line vibrating mesh nebulizers with an HFNC during COPD exacerbation is limited. The aim of this study was to evaluate the clinical response of subjects with COPD exacerbation who require bronchodilator therapy (anticholinergic and β-agonist) by using a vibrating mesh nebulizer in line with an HFNC.
methodsThis was a prospective single-center study performed in a respiratory intermediate care unit that enrolled patients with a diagnosis of COPD exacerbation who required noninvasive ventilation on admission. All the subjects underwent noninvasive ventilation breaks with an HFNC. After clinical stability, pulmonary function tests were performed to assess changes in FEV
resultsForty-six patients with COPD exacerbation were admitted. Five patients who did not use noninvasive ventilation and 10 patients who did not receive bronchodilator treatment with a vibrating mesh nebulizer were excluded. Thirty-one were selected, but 1 subject was secondarily excluded due to loss of data. Finally, 30 subjects were included. The primary outcome was spirometric changes in FEV
conclusionsIn subjects with COPD exacerbation, bronchodilator treatment by using a vibrating mesh nebulizer in line with an HFNC showed a mild but significant improvement in FEV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.